ABT stock falls as topline drops amid baby formula disruption (NYSE:ABT)

Illinois Drugmaker Under Investigation By State Attorney General

Tim Boyle/Getty Images News

Despite a consensus-beating Q4 2022, Abbott Laboratories (NYSE:ABT) lost ~2% pre-market Wednesday as its revenue fell ~12% YoY amid disruption to baby formula production and waning COVID impact.

On a reported basis, revenue for the quarter reached $10.1B taking

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!